Sunrest Lifescience Limited (SUNREST)
Latest quarterly results (H2 FY26)
In its latest reported quarter, H2 FY26, Sunrest Lifescience's revenue was ₹36.8 Cr, and net profit ₹6.6 Cr; the operating margin was 18.3%.
| H2 FY26 (₹ Cr) | Value | YoY | vs prev. half |
|---|---|---|---|
| Revenue | ₹36.8 | — | +8.3% |
| Operating profit | ₹6.8 | — | +175.5% |
| Net profit | ₹6.6 | — | +895.5% |
| EPS (₹) | 3.94 | — | +885.0% |
| Operating margin | 18.3% | — | — |
SUNREST delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 72.73% of the SUNREST shares traded on NSE were taken to delivery, against the stock's own 20-session average of 92.78%. That is lower than usual for this stock. Turnover was only ₹7 lakh, so a handful of trades can move this figure. It traded 3.0 times its average daily volume. It closed at its upper price band (circuit) on 16 Oct.
Delivery in the last 5 sessions: 100.0% · 100.0% · 100.0% · 75.0% · 72.7%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Sunrest Lifescience Limited has announced the dissolution of its proposed Rights Issue after failing to achieve the minimum subscription mandated under Regulation 86 of SEBI ICDR Regulations. The issue was originally open from August 18, 2026, to September 02, 2026, and extended until September 11, 2026. Following this board decision, the company will unblock all applicant funds. With a net worth of ₹19 Cr and debt of ₹9 Cr, the failure to raise capital limits the company's immediate equity financing options.
- Rights issue cancelled due to non-receipt of minimum subscription under SEBI ICDR Regulation 86
- Board decided to unblock applicant funds immediately following the meeting on September 11, 2026
- Subscription period initially ran from August 18, 2026, to September 02, 2026, before being extended to September 11, 2026
- Issue was governed by terms set out in the Letter of Offer dated August 07, 2026
Sunrest Lifescience Limited declared the voting results for its 9th Annual General Meeting held on September 07, 2026. All 4 ordinary and special resolutions were passed with 100% of valid votes polled in favor. Key approvals included the adoption of FY26 financial statements, the re-appointment of two directors retiring by rotation, and approval for material related party transactions for FY 2026-27. Total voting turnout stood at 54.77% across 23,50,400 shares polled.
- All 4 resolutions passed with 100% valid votes cast in favor (23,50,400 votes)
- Overall voter turnout was 54.77% of total 42,91,200 outstanding equity shares
- Promoter group polled 22,96,000 votes (100% turnout of their holdings), while public non-institutional turnout was 2.73% (54,400 votes)
- Approved material related party transactions for FY 2026-27 as a Special Resolution
Sunrest Lifescience Limited conducted its 09th Annual General Meeting on September 07, 2026, via Video Conferencing. Key agenda items placed for shareholder approval included the adoption of FY26 standalone and consolidated financial statements and the re-appointment of directors retiring by rotation. Additionally, a special resolution was tabled to approve material Related Party Transactions for FY 2026-27. Voting results will be declared separately under SEBI Regulation 44.
- 09th Annual General Meeting held on September 07, 2026, starting at 12:30 P.M. and concluding at 12:55 P.M.
- Remote e-voting window was open from September 04, 2026 (9:00 A.M.) to September 06, 2026 (5:00 P.M.)
- Special Resolution proposed for approving material Related Party Transactions for FY 2026-27
- Auditors' reports for FY ended March 31, 2026 contained no qualifications or adverse remarks
Sunrest Lifescience Limited has approved an extension of its ongoing Rights Issue closing date by 9 days from September 2, 2026, to September 11, 2026. The issue offers 1 equity share for every 1 equity share held (1:1 ratio) at an issue price of Rs 35 per share. The issue originally opened on August 18, 2026. The extension is intended to provide eligible shareholders additional time to apply for their rights entitlements.
- Rights issue closing date extended by 9 days from September 02, 2026, to September 11, 2026
- Rights issue ratio stands at 1:1 (1 equity share for every 1 share held)
- Issue price fixed at Rs 35 per equity share
- Issue opened on August 18, 2026
Sunrest Lifescience announced an operational update regarding its 51.49%-owned subsidiary, Hetvi Lifesciences Private Limited. The subsidiary has an order valued at approximately ₹9.22 Crore from Gujarat Medical Services Corporation Limited. To date, work executed and delivered under this contract totals ₹80.76 Lakhs, with management noting that execution is progressing according to planned operational timelines.
- Total order value from Gujarat Medical Services Corporation Limited is approx ₹9.22 Crore
- Work executed and delivered till date stands at ₹80.76 Lakhs
- Contract is executed through subsidiary Hetvi Lifesciences Private Limited (51.49% holding)
Sunrest Lifescience has issued notice for its 9th Annual General Meeting (AGM) to be held on September 7, 2026. The company reported a significant improvement in H1 FY26 net profit margins to 6.00% from 0.76% in the previous year. However, the annual report highlights contingent liabilities including income tax demands of Rs 1.50 Cr for AY 2020-21 and Rs 0.04 Cr for AY 2019-20. Additionally, the company has extended a corporate guarantee of Rs 37 lakhs for Trilend Pharmaceuticals.
- Annual General Meeting scheduled for September 07, 2026, via Video Conferencing.
- Contingent liabilities include an Income Tax demand of Rs 1.50 Cr for AY 2020-21, representing ~8% of the company's Rs 19 Cr net worth.
- Net Profit Margin for H1 FY26 stood at 6.00%, a sharp increase from 0.76% in H1 FY25.
- Corporate guarantee of Rs 37 lakhs provided for working capital loans of Trilend Pharmaceuticals Private Limited.
- Inventory valuation adjustment of Rs 100 lakhs previously identified as a risk factor due to clerical errors.
Sunrest Lifescience has issued its Annual Report for FY 2025-26 and scheduled its 9th Annual General Meeting for September 07, 2026. The company reported a strong March 2026 quarter with revenue of Rs 36.82 Cr and PAT of Rs 6.57 Cr. However, the report highlights contingent liabilities including a Rs 1.50 Cr income tax demand for AY 2020-21 and a Rs 37 lakh corporate guarantee for Trilend Pharmaceuticals. Investors should note previous disclosures regarding a Rs 100 lakh inventory valuation adjustment due to clerical errors.
- Annual General Meeting (AGM) scheduled for September 07, 2026, via Video Conferencing.
- Reported contingent liability of Rs 1.50 Cr for income tax demands pertaining to AY 2020-21.
- Issued an unconditional corporate guarantee of Rs 37 lakhs for Trilend Pharmaceuticals Private Limited.
- March 2026 quarterly revenue reached Rs 36.82 Cr, a significant increase from previous periods.
- Promoter holding remains steady at 53.5% as of March 2026.
Sunrest Lifescience has scheduled its 9th Annual General Meeting for September 7, 2026, to adopt FY26 financial statements and re-appoint a director. The company reported a consolidated net profit margin of 6.00% for H1 FY26, a significant jump from 0.76% in H1 FY25. The annual report highlights contingent liabilities including a Rs 37 lakh corporate guarantee and tax demands totaling Rs 1.54 cr. Investors should note the company's reliance on its 51.49% subsidiary, Hetvi Lifesciences, for growth.
- 9th Annual General Meeting scheduled for September 7, 2026, at 12:30 P.M. IST via Video Conferencing.
- Contingent liability includes a corporate guarantee of Rs 37 lakhs issued for Trilend Pharmaceuticals.
- Income tax demands not acknowledged as debt total Rs 1.54 cr across assessment years 2019-20 and 2020-21.
- Net Profit Margin improved to 6.00% in H1 FY26 from 0.76% in H1 FY25.
- Company maintains a 51.49% stake in subsidiary Hetvi Lifesciences Private Limited to drive market expansion.
Sunrest Lifescience Limited has scheduled its 9th Annual General Meeting (AGM) for September 7, 2026, to be conducted via video conferencing. The board has established August 28, 2026, as the cut-off date for determining shareholder eligibility for e-voting. Key agenda items include the re-appointment of directors Amitbhai Shambhulal Thakkar and Nikhilkumar Yashvntlal Thakkar, and the approval of material related party transactions for the 2026-27 financial year. This follows a quarter (Mar 2026) where the company reported a net profit of ₹6.57 cr.
- 9th Annual General Meeting scheduled for Monday, September 7, 2026, at 12:30 P.M.
- Cut-off date for e-voting eligibility fixed as Friday, August 28, 2026.
- Remote e-voting period set from September 4, 2026 (09:00 A.M.) to September 6, 2026 (05:00 P.M.).
- Board to seek shareholder approval for Material Related Party Transactions for FY 2026-2027.
- Re-appointment of two directors, Mr. Amitbhai Thakkar and Mr. Nikhilkumar Thakkar, proposed for the meeting.
Sunrest Lifescience has finalized a 1:1 rights issue, offering one new equity share for every existing share held as of the record date. The issue price is set at Rs 35 per share, representing a 12.5% discount to the current market price of Rs 40. The record date is fixed for August 10, 2026, leaving a very short window for investor action. This move will double the company's outstanding shares, resulting in significant immediate EPS dilution.
- Rights entitlement ratio fixed at 1:1, effectively doubling the share count
- Issue price set at Rs 35 per share, a discount of Rs 5 from the current price of Rs 40
- Record date for eligibility established as August 10, 2026
- International Securities Identification Number (ISIN) for Rights Entitlement is INE0PLZ20020
- Board meeting for final approval concluded within 30 minutes on August 07, 2026
Sunrest Lifescience has announced August 10, 2026, as the record date for its upcoming Rights Issue. The company is offering shares in a 1:1 ratio, meaning eligible shareholders will receive one new equity share for every one share held. This corporate action will double the company's total number of outstanding shares if fully subscribed. While the issue price was not disclosed in this specific filing, the face value is confirmed at ₹10 per share.
- Rights entitlement ratio fixed at 1:1 (one new share for every one held)
- Record date for eligibility established as August 10, 2026
- Face value of the rights equity shares is ₹10 per share
- Announcement follows a period where the company reported a March 2026 quarterly PAT of ₹6.57 cr
Sunrest Lifescience has announced a 1:1 rights issue to raise approximately Rs 15.02 crore by issuing 42.91 lakh shares. The issue price of Rs 35 represents a narrow 4.1% discount to the current market price of Rs 36.5. The record date is set for August 10, 2026, with the subscription period running from August 18 to September 2, 2026. This is a significant capital infusion, representing nearly 79% of the company's current net worth of Rs 19 crore.
- Rights ratio of 1:1 will double the total outstanding shares to 85,82,400
- Issue price of Rs 35 per share includes a premium of Rs 25 over the Rs 10 face value
- Total fundraise amount is approximately Rs 15.02 crore based on 42,91,200 shares
- Record date for eligibility is August 10, 2026, with the issue closing on September 2, 2026
- Issue price is at a narrow 4.1% discount to the current market price of Rs 36.5
Financial Performance
Revenue Growth by Segment
Total income from operations for the half-year ended September 30, 2025, reached INR 3,341.76 lakhs, representing a 13.34% growth compared to INR 2,948.39 lakhs in the same period of the previous year. Segment-specific growth percentages are not disclosed in the available documents.
Profitability Margins
Net Profit Margin for H1 FY26 (period ended September 30, 2025) stood at 6.00%, a significant improvement from the 0.76% margin recorded in H1 FY25. This margin expansion was driven by a sharp increase in consolidated profit after tax to INR 200.56 lakhs from INR 22.57 lakhs YoY.
EBITDA Margin
Consolidated Profit before Tax for H1 FY26 was INR 262.35 lakhs (7.85% of revenue), compared to INR 77.41 lakhs (2.62% of revenue) in H1 FY25, indicating a 239% increase in core operational profitability.
Operational Drivers
Raw Material Costs
Total expenses for H1 FY26 were INR 3,079.41 lakhs, representing 92.15% of revenue. This is a decrease from H1 FY25 where expenses represented 97.38% of revenue, suggesting improved procurement or cost management strategies.
Strategic Growth
Growth Strategy
The company is leveraging its 51.49% stake in its Indian subsidiary, Hetvi Lifesciences Private Limited, to expand its market presence. Growth is further supported by the industry's rising healthcare needs and increased chronic disease prevalence, which the company aims to address through its lifescience product portfolio.
Products & Services
Lifescience and pharmaceutical products, including medicines and healthcare solutions.
Brand Portfolio
Sunrest
Market Expansion
The company is focusing on the lifescience sector, targeting growth driven by aging populations and heightened emphasis on affordable healthcare access.
Strategic Alliances
The company operates with an Indian subsidiary, Hetvi Lifesciences Private Limited, in which it holds a 51.49% controlling interest.
External Factors
Industry Trends
The industry is evolving through technological innovation and regulatory shifts. Future growth is expected to be driven by a 15-20% increase in chronic disease prevalence and a global shift toward affordable healthcare access, positioning Sunrest to capture demand in the lifescience segment.
Competitive Landscape
The industry is characterized by strong fundamentals and shifting market dynamics, requiring companies to innovate and maintain high standards of regulatory compliance to remain competitive.
Competitive Moat
The company's moat is built on its established presence in the lifescience sector and its subsidiary network. Sustainability depends on maintaining rigorous internal financial controls and adapting to shifting market dynamics and regulatory standards.
Macro Economic Sensitivity
The company is sensitive to rising healthcare needs and aging populations, which serve as fundamental drivers for the pharmaceutical industry's growth.
Consumer Behavior
Increased emphasis on affordable healthcare and rising demand for treatments for chronic diseases are primary consumer trends affecting demand for Sunrest's products.
Regulatory & Governance
Industry Regulations
Operations are governed by the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 33 regarding the disclosure of financial results and internal financial controls.
Taxation Policy Impact
Total tax expense for H1 FY26 was INR 61.27 lakhs, representing an effective tax rate of approximately 23.35% on a consolidated profit before tax of INR 262.35 lakhs.
Risk Analysis
Key Uncertainties
The primary uncertainty involves internal control weaknesses, as evidenced by the clerical error in inventory valuation that required a significant financial restatement (INR 100 lakh adjustment).
Third Party Dependencies
The company relies on other auditors for the audit of its subsidiary, Hetvi Lifesciences Private Limited, which contributes to the consolidated financial results.
